Trial Comparing Radiotherapy with Dual Immunotherapy in Locally Advanced Rectal Cancer
A multicenter trial is evaluating the efficacy of different radiotherapy regimens combined with dual immunotherapy in LARC patients.
Asset / Drug
Drug and asset intelligence for paromlimab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.